Big Pharma Split (TSX:PRM) Total Noninterest Expense: C$0.52 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:PRM Big Pharma Split Corp TSX:PRM
7 GF Score
Price C$11.61
GF Value C$1.80
View Full Analysis

What is Big Pharma Split Total Noninterest Expense?

Big Pharma Split TSX:PRM 7 Total Noninterest Expense is C$0.52 Mil as of Dec. 2025. GuruFocus rates TSX:PRM with a GF Score™ of 7/100 and a GF Value™ of C$1.80.

Big Pharma Split's Total Noninterest Expense for the six months ended in Dec. 2025 was C$0.27 Mil. Big Pharma Split's Total Noninterest Expense for the trailing twelve months (TTM) ended in Dec. 2025 was C$0.52 Mil.

Big Pharma Split Total Noninterest Expense Related Terms

Big Pharma Split Total Noninterest Expense Historical Data

* Premium members only.

The historical data trend for Big Pharma Split's Total Noninterest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Big Pharma Split Total Noninterest Expense Chart

Big Pharma Split Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Noninterest Expense
Get a 7-Day Free Trial Premium Member Only 0.51 0.57 0.45 0.42 0.52

Big Pharma Split Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Noninterest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.25 0.17 0.26 0.27
TSX:PRM
7GF Score
Big Pharma Split Corp TSX:PRM
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Big Pharma Split Total Noninterest Expense Calculation

Total Noninterest Expense is any expenses incurred that not related to interest. It includes:
Selling, General, & Admin. Expense
Occupancy
Equipment
Professional fees
Amortization of intangibles
Any other special income/charges (too numerous to list)
Some banks can do choose to report each of these items separately. Yet, there are a variety of noninterest expense which are simply too numerous to list.

Total Noninterest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was C$0.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Noninterest Expense of C$0.52 Mil mean?
Big Pharma Split (TSX:PRM) has a Total Noninterest Expense of C$0.52 Mil as of Dec. 2025. Total noninterest expense is any expenses incurred that not related to interest. View historical data on Big Pharma Split and its competitors.
Is Big Pharma Split's Total Noninterest Expense too high?
Big Pharma Split's current Total Noninterest Expense is C$0.52 Mil. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's Total Noninterest Expense compare to BLK and BX?
Big Pharma Split's Total Noninterest Expense of C$0.52 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Noninterest Expense for an Asset Management company?
A good Total Noninterest Expense depends on the Asset Management industry context. However, Total Noninterest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Noninterest Expense mean?
A high Total Noninterest Expense can signal that a stock is expensive relative to its fundamentals. Total noninterest expense is any expenses incurred that not related to interest. View historical data on Big Pharma Split and its competitors. Big Pharma Split's current Total Noninterest Expense is C$0.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current Total Noninterest Expense of C$0.52 Mil. The stock's GF Value™ is C$1.80, compared to a current price of C$11.61 — trading 545% above its estimated fair value. The current Total Noninterest Expense is C$0.52 Mil. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Noninterest Expense calculated?
Total Noninterest Expense is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current Total Noninterest Expense is C$0.52 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Big Pharma Split (TSX:PRM) Overvalued in 2026?

Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued. The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.

Key valuation signals for TSX:PRM:

  • Total Noninterest Expense: C$0.52 Mil
  • GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
  • GF Score™: 7/100

No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Big Pharma Split Business Description

Other Exchanges PRM.PR.A.PFD:Canada
Address 610 Chartwell Road, Suite 204, Oakville, ON, CAN, L6J 4A5
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score

Get the complete analysis for TSX:PRM

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$11.61
Price
C$1.80
GF Value